TuHURA Biosciences (NASDAQ:HURA) Announces Earnings Results

TuHURA Biosciences (NASDAQ:HURA) announced its quarterly earnings results on Friday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04, FiscalAI reports.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA traded down $0.06 during trading on Friday, reaching $1.39. 371,851 shares of the company’s stock traded hands, compared to its average volume of 507,191. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The company has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $2.00. The firm has a market cap of $88.58 million, a PE ratio of -2.57 and a beta of -0.23.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, October 27th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, TuHURA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $9.50.

About TuHURA Biosciences

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.